Literature DB >> 3526877

Infection in cancer patients. A continuing association.

G P Bodey.   

Abstract

Infection remains a major complication in patients with malignant disease. There are many factors predisposing to infection in this patient population, including local factors due to the tumor, specific deficiencies in host defense mechanisms due to certain malignant processes, and deficiencies in host defense mechanisms secondary to cancer chemotherapy. Neutropenia is probably the most important factor predisposing to infection in cancer patients. These patients require prompt broad-spectrum antibiotic therapy when fever develops. The majority of infections occurring in this patient population are caused by gram-negative bacilli and cure rates usually are between 65 and 75 percent. The most important prognostic factor is whether or not the neutrophil count recovers during the course of infection. Fungal infections have increased in frequency in neutropenic patients and often present as fevers of unknown origin. Increasingly, neutropenic patients are receiving antifungal agents as empiric therapy for persistent fever that fails to respond to antibacterial antibiotics. The most critical factor in recovery from fungal infection is remission of the underlying malignant disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526877     DOI: 10.1016/0002-9343(86)90510-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  65 in total

Review 1.  Role of itraconazole in haematology/oncology.

Authors:  N A Pandya; A A Atra; U Riley; C R Pinkerton
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

2.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 3.  [Therapy of infections in patients with acute leukemia].

Authors:  W Hiddemann; G Maschmeyer; H Link; M Helmerking; D Adam
Journal:  Med Klin (Munich)       Date:  1997-07-15

4.  Neoplastic fever: all who shiver are not infected.

Authors:  Kenneth V I Rolston
Journal:  Support Care Cancer       Date:  2005-07-07       Impact factor: 3.603

5.  A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients.

Authors:  A Böhme; G Just-Nübling; L Bergmann; P M Shah; W Stille; D Hoelzer
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

6.  Three cases of infection with Fusarium species in neutropenic patients.

Authors:  M Nucci; N Spector; S Lucena; P C Bacha; W Pulcheri; A Lamosa; A Derossi; M J Caiuby; J Macieira; H P Oliveira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

7.  Cellular and cytokine correlates of mucosal protection in murine model of oral candidiasis.

Authors:  S Elahi; G Pang; R Clancy; R B Ashman
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

8.  Penetration of oral fluconazole into gynecological tissues.

Authors:  H Mikamo; K Kawazoe; Y Sato; K Izumi; T Ito; K Ito; T Tamaya
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

9.  Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.

Authors:  M Nakamura; W B Weil; D B Kaufman
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

10.  Prophylactic use of fluconazole in neutropenic cancer patients.

Authors:  K Yamaç; E Senol; R Haznedar
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.